NMR screening of low molecular weight inhibitors targeting the papain-like protease (PLPro) of SARS-CoV-2

🧬 buff.ly/pdzbYbm

#SARSCoV2 #PLPro #NMRspectroscopy

Fighting Back: Unmasking SARS-CoV-2 PLpro's Drug Resistance Hotspots The global battle against SARS-CoV-2, the virus behind COVID-19, continues to evolve. While the pandemic may be winding down, the virus and its capacity to mutate remain a significant challenge to pub...

COVID-19's not done evolving. New research from Wang Lab @Rutgers identifies resistance mutations in SARS-CoV-2’s papain-like protease—E167, Y268, Q269—that weaken PLpro inhibitors like Jun12682 & PF-07957472. go.njmicrobe.org/i8Ff4M #COVID19 #AntiviralResistance #PLpro #Rutgers #SARSCoV2

Papain‐Like Protease of SARS‐CoV‐2 Induces Intestinal Inflammation via the ISG15 Pathway: Identification of Natural Compound Inhibitors The SARS-CoV-2 papain-like protease (PLpro) is a multifunctional viral protein that facilitates viral assembly and disrupts host immune responses by removing interferon-stimulated gene 15 (ISG15) mod...

onlinelibrary.wiley.com/doi/10.1002/...

"Our results highlight the potential of targeting the #PLpro / #ISG15 interaction as a therapeutic strategy against #SARSCoV2."

Scientists stop long-COVID symptoms in mice using a new antiviral compound Australian scientists developed a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical efficacy in reducing both acute and long COVID symptoms in mice.

Scientists stop long-COVID symptoms in mice using a new antiviral compound 🧬🧪🐁 www.news-medical.net/news/2025040... #LongCOVID #Antiviral #PLpro #SARSCoV2 #COVID19 #DrugDiscovery #Immunology #Neuroscience #Biotech @naturecomms.bsky.social

A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID - Nature Communications A novel antiviral targeting the SARS-CoV-2 PLpro protease shows strong efficacy in a mouse model, preventing lung pathology and reducing brain dysfunction. The study provides proof-of-principle that P...

Thrilled to share our paper in Nature Communications – A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. #LongCOVID #PLpro #COVID19 #SARSCoV2 #Antivirals www.nature.com/articles/s41...

A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID - Nature Communications A novel antiviral targeting the SARS-CoV-2 PLpro protease shows strong efficacy in a mouse model, preventing lung pathology and reducing brain dysfunction. The study provides proof-of-principle that P...

Excited to share that our collaborative work on PLpro inhibitors is published! Using a model that replicates symptoms seen in long COVID patients, we show that a potent antiviral can prevent long-term disease. A big step forward in long COVID therapy. #LongCOVID #PLpro #COVID19 #SARSCoV2 #Antivirals

Tackling the 'silent pandemic': Study puts first long COVID treatment on horizon Researchers have shown a new drug compound can prevent long COVID symptoms in mice—a landmark finding that could lead to a future treatment for the debilitating condition.

Another PLpro-targeting drug shows promise—this one prevented long COVID-like symptoms in mice. Early research, but it’s part of a growing trend: scientists may be finding a real way to stop long COVID at its source. #LongCovid #PLpro #COVID19